Abstract
Schizophrenia is a major debilitating, complex and costly illness tha t strikes 1% of the world’s population. It is found in every society from the most primitive to the largest and most technologically advanced society. The excessive degree of cigarette smoking exhibited by schizophrenic patients suggests that they might be self - medicating to ameliorate to some extent the characteristic positive, negative and cognitive symptoms associated with the dise ase. Morphological examinations found alterations in nicotinic receptors in postmortem tissue from schizophrenic individuals compared to controls, especially in the α7 and α4β2 subtypes. These results have spurred the development of new pharmaceuticals specifically designed to modulate nicotinic recep tor function. The initial results from clinical trials of these new drugs appea r promising, potentially opening new avenues of treatment for this devastating disease. In the present review article, the authors have described various neuromodulators such as D opamine, Glutamate, Acetylcholine, Serotonin, GABA etc. responsible for causi ng
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.